JNJ stock: buy or sell?
May 21st, 2019
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.
Should I buy JNJ stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Johnson & Johnson stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Johnson & Johnson stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 9 ratings published for JNJ stock in the last month. The general sentiment of these ratings is bullish for JNJ stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-5-6||Wells Fargo & Co||n/a||Outperform|
|2019-5-16||Credit Suisse Group||n/a||Outperform|
|2019-4-17||Morgan Stanley||Equal Weight||Equal Weight|
|2019-4-17||Credit Suisse Group||Outperform||Outperform|
|2019-1-2||Morgan Stanley||Equal Weight||Equal Weight|
|2019-1-14||Wells Fargo & Co||Outperform||Outperform|
JNJ stock analysis
Johnson & Johnson shares stayed constant -0.22% to $138.12 today.
Shares of Johnson & Johnson closed today at $138.12 and stayed stable a bad -0.22%. Since price and SMA200d lines crossed up on January, JNJ climbed $8.65 (6.68%).
Johnson & Johnson shares remained steady -0.35% this week, ending at $138.12. Counting this, it's been 3 red weeks in a row, sliding $-3.89 or a -2.77%.
Since price and SMA40w lines crossed up late January, JNJ climbed $10.73 (8.42%). Far behind is the all-time high Johnson & Johnson marked early December but price is just -6.68% below that top.
JNJ stock price history
JNJ stock went public on August 18th, 1980 with a price of $0.011. Since then, JNJ stock surged a 1,381,100.00%, with a yearly average of 36,344.70%. If you had invested $1,000 in JNJ stock in 1980, it would worth $13,811,000.00 today.
1: Adjusted price after possible price splits or reverse-splits.
JNJ stock historical price chart
JNJ stock reached all-time highs on December with a price of $148.01.
JNJ stock price target is $145.90How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' JNJ stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we found 9 price predictions for Johnson & Johnson stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-5-6||Wells Fargo & Co||Reiterates||$152.00||$157.00||3.3%|
|2019-5-16||Credit Suisse Group||Raises Target||$152.00||$156.00||2.6%|
|2019-4-17||Raymond James||Raises Target||$145.00||$147.00||1.4%|
|2019-4-17||Morgan Stanley||Raises Target||$134.00||$145.00||8.2%|
|2019-4-17||Credit Suisse Group||Raises Target||$151.00||$152.00||0.7%|
|2019-1-2||Morgan Stanley||Lowers Target||$153.00||$130.00||-15%|
|2019-1-14||Wells Fargo & Co||Reiterates||$162.00||$152.00||-6.2%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on Apr/16, Johnson & Johnson remained stable a slightly good 1.17%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Johnson & Johnson annual sales rose a shining 6.71% to $81,581.00 million USD from $76,450.00 marked in 2017. When comparing 2018 vs 2017, instead, profit margin (that is, the net income divided by revenues) climbed a 17.05% to 18.75%. Johnson & Johnson fiscal year ends in December, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Johnson & Johnson TTM sales up to March 2019 were $81,593.00 and income $14,679.00 M USD. When comparing this TTM figures with the last reported annuality, we can review Johnson & Johnson business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, remained stable a neutral 0.01%. Aligned with this, profit margin (net income/sales) stayed stable at 18.75%.
|2013||$71,260 M||-||$13,830 M19.4%||-|
|2014||$74,331 M||4.31%||$16,323 M22.0%||18.03%|
|2015||$70,074 M||-5.73%||$15,409 M22.0%||-5.60%|
|2016||$71,890 M||2.59%||$16,540 M23.0%||7.34%|
|2017||$76,450 M||6.34%||$1,300 M1.7%||-92.14%|
|2018||$81,581 M||6.71%||$15,297 M18.8%||1,076.69%|
|TTM||$81,593 M||0.01%||$14,679 M18.0%||-4.04%|
Quarterly financial resultsJohnson & Johnson posted $20,021.00 M in sales for 2019-Q1, a -1.83% less compared to previous quarter. Reported quarter income marked $3,749.00 million with a profit margin of 18.73%. Profit margin raised a 3.81% compared to previous quarter when profit margin was 14.92%. When comparing turnover to same quarter last year, Johnson & Johnson sales marked a tight movement and stayed steady a 0.06%.
|2017-Q2||$18,850 M||-||$3,830 M20.3%||-|
|2017-Q3||$19,650 M||4.24%||$3,760 M19.1%||-1.83%|
|2017-Q4||$20,195 M||2.77%||$-10,713 M-53.0%||-384.92%|
|2018-Q1||$20,009 M||-0.92%||$4,367 M21.8%||-140.76%|
|2018-Q2||$20,830 M||4.10%||$3,954 M19.0%||-9.46%|
|2018-Q3||$20,348 M||-2.31%||$3,934 M19.3%||-0.51%|
|2018-Q4||$20,394 M||0.23%||$3,042 M14.9%||-22.67%|
|2019-Q1||$20,021 M||-1.83%||$3,749 M18.7%||23.24%|
Johnson & Johnson ownershipWhen you are planning to invest in shares of a company, it's worth to review its ownership structure.
Johnson & Johnson shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.07% of all shares.
In case of Johnson & Johnson stock, 69.23% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for JNJ stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Johnson & Johnson:
|Market cap||$367.4 B||$133.8 B||$193.7 B||$107.4 B||$117.6 B|
|Total shares||2,660.0 M||1,760.0 M||4,920.0 M||920.8 M||1,340.0 M|
|Float shares||2,650.0 M||1,750.0 M||2,440.0 M||802.0 M||1,340.0 M|
|- Institutional holdings (%)||69.2%||76.5%||11.0%||81.5%||84.2%|
|- Insider holdings (%)||0.1%||0.7%||0.0%||0.1%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$138.08 - $139.57|
|Average true range||$1.97|
|50d mov avg||$138.33|
|100d mov avg||$135.03|
|200d mov avg||$135.84|
Johnson & Johnson performanceTo better understand Johnson & Johnson performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Johnson & Johnson to , GlaxoSmithKline, Eli Lilly and, Medtronic, Merck, Novartis, Pfizer, and Stryker:
|LLYEli Lilly and||-5.46%||4.42%||43.91%|
Johnson & Johnson competitorsOne check before trading any stock is to have a look a list of its competitors, in this case for Johnson & Johnson. We selected 9 companies as Johnson & Johnson competitors as they are in the same industry or have similar market objectives.
- GlaxoSmithKline (GSK)
- Eli Lilly and (LLY)
- Medtronic (MDT)
- Merck (MRK)
- Novartis (NVS)
- Pfizer (PFE)
- Stryker (SYK)
Latest JNJ stock news
- InvestorPlaceWhy Investors Should Buy Johnson & Johnson Stock on Every DipMay 7, 2019
- Seeking AlphaJohnson & Johnson Comes Out Of Gate With First Approval For Targeted Bladder Cancer TherapyApril 29, 2019
- InvestorPlaceLegal Risk Weighs on Johnson & Johnson StockApril 26, 2019
- Seeking AlphaJohnson & Johnson Looks To Help Type 2 Diabetes Patients With Key AdvancementApril 17, 2019
- InvestorPlaceWhy The Rally In Johnson & Johnson Stock May Top Out At $150April 17, 2019